Auf dieser Seite
01ACAD Preis
02Momentaufnahme
03Chart
05Über uns
06Performance
07Bewertung & Kennzahlen
14Erträge
15Vollständige Fundamentaldaten
16Erklärungen
17Institutionelle Eigentümer (13F)
18Aktivisten & 5%+-Eigentümer
19Unternehmensinsider
20ETF-Besitz
21Konsens
22Peers
23Nachrichten
25Handelssignale
26Meine Kennzahlen
ACAD ACADIA Pharmaceuticals Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 5, 2026
$19,95
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$19,5952-Wochen-Tief
$30,9652-Wochen-Hoch
Marktkapitalisierung (MRQ)
$3.43B
P/E (TTM)
8.9
EPS (TTM)
$2.23
Umsatz (TTM)
$1.14B
Ihre Abzeichen
52W-Spanne
$20–$31
Analystenbewertung
BUY
Kursziel
$32
P/E
8.9
ROE
35.7%
Nettogewinnmarge
33.4%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
ACAD Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$19.95
Marktkapitalisierung (MRQ)
$3.43B
P/E (TTM)
8.9
EPS (TTM)
$2.23
Umsatz (TTM)
$1.14B
ROE (TTM)
35.7%
52W-Spanne
$20–$31
ACAD Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über ACADIA Pharmaceuticals Inc. - Common Stock Unternehmensübersicht von Wikipedia
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Product development
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
History
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
== References ==
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BrancheBiotechnology
Mitarbeiter796
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$1.07B2016-12-31 → 2025-12-31
EPS$2.302020-12-31 → 2025-12-31
Freier Cashflow$105M2016-12-31 → 2025-12-31
Nettogewinnmarge33.4%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | ACAD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | 8.95-Jahres-Durchschnitt ≈-18.7 | ≈-18.7 | 13.8 | Unterbewertet | |
| P/S (TTM) | 3.05-Jahres-Durchschnitt ≈5.5 | ≈5.5 | 11.9 | Unterbewertet | |
| K/B (MRQ) | 2.65-Jahres-Durchschnitt ≈6.6 | ≈6.6 | 3.4 | Unterbewertet | |
| Kurs / FCF (TTM) | 23.65-Jahres-Durchschnitt ≈64.0 | ≈64.0 | · | · | |
| Kurs / Cashflow (TTM) | 21.45-Jahres-Durchschnitt ≈63.4 | ≈63.4 | · | · | |
| Kurs / Materieller Buchwert (MRQ) | 2.95-Jahres-Durchschnitt ≈7.3 | ≈7.3 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | ACAD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | 7.6%5-Jahres-Durchschnitt ≈-10.9% | ≈-10.9% | 12.5% | Im Einklang | |
| EBITDA Margin (EBITDA-Marge) | 9.8%5-Jahres-Durchschnitt ≈-10.9% | ≈-10.9% | 12.5% | Im Einklang | |
| Vorgewinnmarge (TTM) | 10.7%5-Jahres-Durchschnitt ≈-8.6% | ≈-8.6% | 16.4% | Im Einklang | |
| Nettogewinnmarge (TTM) | 33.4%5-Jahres-Durchschnitt ≈-4.9% | ≈-4.9% | 10.2% | Im Einklang | |
| ROA (TTM) | 25.6%5-Jahres-Durchschnitt ≈-2.7% | ≈-2.7% | -7.4% | Spitzenklasse | |
| ROE (TTM) | 35.7%5-Jahres-Durchschnitt ≈-5.1% | ≈-5.1% | -10.7% | Spitzenklasse | |
| ROIC | 24.0%5-Jahres-Durchschnitt ≈-11.4% | ≈-11.4% | -3.0% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | ACAD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 3.45-Jahres-Durchschnitt ≈3.8 | ≈3.8 | 6.5 | Geringe Liquidität | |
| Quick Ratio | 1.15-Jahres-Durchschnitt ≈1.4 | ≈1.4 | 5.0 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | ACAD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 11.9%5-Jahres-Durchschnitt ≈20.1% | ≈20.1% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 27.5%5-Jahres-Durchschnitt ≈23.7% | ≈23.7% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 19.4% | · | · | · | |
| EPS YoY (EPS VjV) | 69.1% | · | · | · | |
| Net Income YoY (Nettogewinn YoY) | 72.7% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | ACAD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.85-Jahres-Durchschnitt ≈0.9 | ≈0.9 | 0.4 | Spitzenklasse | |
| Inventory Turnover (Lagerumschlag) | 0.95-Jahres-Durchschnitt ≈1.1 | ≈1.1 | · | · | |
| Receivables Turnover (Forderungsumschlag) | 9.75-Jahres-Durchschnitt ≈9.1 | ≈9.1 | 10.5 | Im Einklang | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$1.3M | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
228.8%
Nächster Bericht
Nov 03, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 11, 2026 | $0.18 | $0.06 | 207.2% |
| 31. März 2026 | Mai 13, 2026 | $0.02 | $0.06 | -68.4% |
| 31. Dezember 2025 | $1.60 | $0.14 | 1044.5% | |
| 30. September 2025 | $0.42 | $0.15 | 178.1% | |
| 30. Juni 2025 | $0.16 | $0.14 | 14.4% | |
| 31. März 2025 | $0.11 | $0.11 | -3.2% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Cost of Revenue | $89M | $82M | $42M | $10M | $19M | $10M | $11M | $12M | $9M | $3M | · | · | |
| Gross Profit | · | · | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M | · | · | |
| R&D Expense | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M | $74M | $61M | |
| SG&A Expense | $549M | $488M | $407M | $369M | $396M | $389M | $326M | $266M | $255M | $186M | $88M | $33M | |
| Operating Expenses | $967M | $727M | $800M | $741M | $655M | $728M | $586M | $471M | $417M | $290M | $165M | $93M | |
| Operating Income | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M | |
| Other Non-op | $2M | $2M | $5M | $4M | $2M | $-997.0K | $997.0K | $-2M | · | · | · | · | |
| Pretax Income | $139M | $258M | $-51M | $-213M | $-168M | $-281M | $-234M | $-244M | $-288M | $-270M | $-164M | $-92M | |
| Income Tax | $-252M | $32M | $10M | $3M | $351.0K | $611.0K | $876.0K | $1M | $1M | $1M | $330.0K | $0 | |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| Shares (Basic) | 168,356,000 | 165,717,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| Shares (Diluted) | 169,919,000 | 166,362,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| EBITDA | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $178M | $320M | $189M | $115M | $147M | $326M | $190M | $135M | $69M | $164M | $102M | $62M | |
| Receivables | $121M | $99M | $98M | $62M | $64M | $48M | $36M | $26M | $17M | $6M | · | · | |
| Inventory | $111M | $92M | $40M | $12M | $14M | $10M | $6M | $4M | $5M | $4M | · | · | |
| Prepaid Expense | $60M | $56M | $39M | $21M | $24M | $26M | $19M | $21M | $8M | $8M | $2M | $1M | |
| Current Assets | $1.06B | $938M | $616M | $508M | $618M | $718M | $760M | $526M | $373M | $548M | $219M | $325M | |
| PP&E (Net) | $8M | $4M | $5M | $6M | $8M | $9M | $3M | $3M | $3M | $3M | $2M | $553.0K | |
| PP&E (Gross) | $17M | $14M | $14M | $14M | $14M | $13M | $9M | $8M | $7M | $6M | $5M | $3M | |
| Accum. Depreciation | $9M | $10M | $10M | $8M | $6M | $4M | $5M | $4M | $4M | $3M | $3M | $2M | |
| Intangibles | $109M | $120M | $65M | $0 | $0 | $1M | $3M | $4M | $6M | $7M | · | · | |
| Other Non-current Assets | $4M | $359.0K | $476.0K | $8M | $4M | $2M | $3M | $2M | $354.0K | $785.0K | $329.0K | $287.0K | |
| Total Assets | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Accounts Payable | $11M | $16M | $18M | $13M | $7M | $8M | $7M | $3M | $9M | $4M | $2M | $2M | |
| Accrued Liabilities | $266M | $379M | $237M | $113M | $89M | $97M | $68M | $56M | $40M | $36M | $20M | $14M | |
| Current Liabilities | $277M | $395M | $254M | $126M | $96M | $106M | $75M | $60M | $49M | $43M | $22M | $16M | |
| Capital Leases | $41M | $42M | $48M | $53M | $56M | $44M | $6M | · | · | · | · | · | |
| Deferred Tax | $11M | $11M | $12M | $13M | $14M | $13M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $19M | $18M | $15M | $9M | $7M | $5M | $3M | $2M | · | · | · | · | |
| Total Liabilities | $337M | $455M | $317M | $187M | $159M | $156M | $84M | $61M | $49M | $43M | $22M | $16M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | $14.0K | $12.0K | $12.0K | $10.0K | $10.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $1.45B | $862M | $808M | |
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B | $-1.22B | $-934M | $-663M | $-498M | |
| AOCI | $1M | $292.0K | $24.0K | $-975.0K | $-192.0K | $36.0K | $297.0K | $-372.0K | $-399.0K | $106.0K | $11.0K | $-9.0K | |
| Stockholders' Equity | $1.23B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M | $200M | $309M | |
| Liabilities + Equity | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Shares Outstanding | 170,309,376 | 166,708,856 | 164,650,219 | 162,064,872 | 161,012,695 | 159,637,771 | 155,275,300 | 143,853,597 | 124,410,552 | 121,367,169 | 101,938,702 | 100,047,331 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $206.0K | |
| Stock-based Comp | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M | $40M | $16M | |
| Deferred Tax | $-250M | $0 | $0 | $3M | $351.0K | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $11M | $15M | $4M | $0 | $1M | $1M | $1M | $1M | $1M | $985.0K | $0 | $0 | |
| Operating Cash Flow | $110M | $158M | $17M | $-114M | $-126M | $-136M | $-151M | $-167M | $-218M | $-208M | $-122M | $-66M | |
| CapEx | $5M | $523.0K | $50.0K | $0 | $1M | $8M | $1M | $2M | $812.0K | $2M | $2M | $180.0K | |
| Investing Cash Flow | $-303M | $-31M | $32M | $73M | $-71M | $193M | $-166M | $-71M | $92M | $-262M | · | · | |
| Stock Issued | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Net Stock Activity | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Financing Cash Flow | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $534M | · | · | |
| Net Change in Cash | $-143M | $134M | $74M | $-33M | $-179M | $137M | $55M | $68M | $-94M | $63M | $40M | $50M | |
| Taxes Paid | $25M | $20M | $6M | $2M | $1M | $1M | $2M | $1M | $1M | $-365.0K | $415.0K | · | |
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M | $-144M | $-152M | $-170M | $-219M | $-212M | $-124M | $-67M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% | · | · | |
| Operating Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| Net Margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% | |
| Pretax Margin | 13.0% | 26.9% | -7.0% | -41.3% | -34.6% | -63.6% | -69.1% | -109.0% | -230.8% | -1558.2% | -269037.7% | · | |
| EBITDA Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| ROA | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.5% | -53.0% | -61.2% | -69.3% | -60.1% | -35.9% | |
| ROE | 38.1% | 34.6% | -15.4% | -52.3% | -30.3% | -43.9% | -33.9% | -69.8% | -67.8% | -75.6% | -64.6% | -37.6% | |
| ROIC | 24.0% | 27.6% | -20.4% | -56.5% | -31.6% | -45.8% | -35.4% | -51.9% | -87.5% | -52.9% | -82.6% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 | 6.8 | 10.2 | 8.8 | 7.6 | 12.9 | 10.0 | 20.5 | |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 | 3.5 | 3.0 | 2.7 | 1.8 | 4.0 | 4.7 | 3.9 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.9 | 1.2 | 1.6 | 0.8 | 0.9 | 1.3 | 2.2 | · | 1.9 | 1.5 | · | · | |
| Receivables Turnover | 9.7 | 9.7 | 9.1 | 8.2 | 8.6 | 10.5 | 11.0 | 10.3 | 10.7 | 5.9 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.21 | $4.40 | $2.62 | $2.47 | $3.36 | $3.93 | $4.50 | $3.33 | $2.69 | $4.27 | $1.96 | $3.09 | |
| Revenue / Share | $6.31 | $5.76 | $4434.39 | $3199.07 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $0.65 | $0.95 | $101.95 | $-705.30 | · | · | · | · | · | · | · | · | |
| Cash / Share | $1.04 | $1.92 | $1.15 | $0.71 | $0.92 | $2.04 | $1.22 | $0.94 | $0.56 | $1.35 | $1.00 | $0.62 | |
| EPS (TTM) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.9% | 31.9% | 40.5% | 6.8% | 9.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.5% | 25.5% | 18.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 69.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 72.7% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Net Income TTM | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| Market Cap | $4.55B | $3.06B | $5.16B | $2.58B | $3.76B | $8.53B | $6.64B | $2.33B | $3.75B | $3.50B | $3.63B | $3.18B | |
| P/E | 11.6 | 13.5 | -84.6 | -11.9 | -22.2 | -29.9 | · | · | · | · | · | · | |
| P/S | 4.2 | 3.2 | 7.1 | 5.0 | 7.8 | 19.3 | 19.6 | 10.4 | 30.0 | 202.0 | 59575.7 | 26470.9 | |
| P/B | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.6 | 9.5 | 4.9 | 11.2 | 6.8 | 18.2 | 10.3 | |
| P / Tangible Book | 4.1 | 5.0 | 14.1 | 6.4 | 6.9 | 13.6 | · | · | · | · | · | · | |
| P / Cash Flow | 41.4 | 19.4 | 308.7 | -22.6 | -29.9 | -62.7 | -44.0 | -13.9 | -17.2 | -16.6 | -29.8 | -47.8 | |
| P / FCF | 43.3 | 19.5 | 309.6 | -22.6 | -29.6 | -59.4 | -43.6 | -13.7 | -17.1 | -16.5 | -29.3 | -47.7 | |
| Earnings Yield | 8.6% | 7.4% | -1.2% | -8.4% | -4.5% | -3.4% | · | · | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $268M | $284M | $279M | $265M | $244M | $260M | $250M | $242M | $206M | $231M | $212M | $165M | $118M | $136M | $131M | |
| Cost of Revenue | $28M | $25M | $26M | $22M | $21M | $20M | $22M | $19M | $18M | $23M | $18M | $15M | $7M | $2M | $2M | $2M | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $213M | $197M | $158M | $117M | $134M | $129M | |
| R&D Expense | $82M | $77M | $85M | $88M | $78M | $78M | $101M | $67M | $76M | $60M | $67M | $157M | $59M | $69M | $76M | $81M | |
| SG&A Expense | $160M | $171M | $156M | $133M | $134M | $126M | $130M | $133M | $117M | $108M | $111M | $98M | $96M | $101M | $104M | $78M | |
| Operating Expenses | $270M | $273M | $267M | $243M | $232M | $225M | $106M | $219M | $212M | $191M | $196M | $269M | $162M | $172M | $183M | $162M | |
| Operating Income | $38M | $-5M | $17M | $36M | $32M | $19M | $154M | $32M | $30M | $15M | $35M | $-58M | $3M | $-54M | $-46M | $-31M | |
| Other Non-op | $647.0K | $542.0K | $596.0K | $593.0K | $594.0K | $588.0K | $575.0K | $576.0K | $386.0K | $286.0K | $0 | $2M | $-1M | $5M | $2M | $2M | |
| Pretax Income | $46M | $4M | $26M | $45M | $40M | $28M | $161M | $39M | $37M | $21M | $40M | $-52M | $6M | $-45M | $-41M | $-26M | |
| Income Tax | $15M | $344.0K | $-247M | $-27M | $14M | $9M | $17M | $6M | $4M | $4M | $-6M | $13M | $5M | $-2M | $835.0K | $768.0K | |
| Net Income | $32M | $4M | $274M | $72M | $27M | $19M | $144M | $33M | $33M | $17M | $46M | $-65M | $1M | $-43M | $-42M | $-27M | |
| EPS (Basic) | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| EPS (Diluted) | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| Shares (Basic) | 171,603,000 | 170,517,000 | · | 168,836,000 | 167,827,000 | 166,808,000 | · | 165,974,000 | 165,551,000 | 164,798,000 | · | 164,234,000 | 163,458,000 | 162,263,000 | · | 161,852 | |
| Shares (Diluted) | 172,851,000 | 172,706,000 | · | 170,650,000 | 168,681,000 | 167,668,000 | · | 166,178,000 | 166,174,000 | 166,623,000 | · | 164,234,000 | 165,046,000 | 162,263,000 | · | 161,852 | |
| EBITDA | $38M | $-5M | · | $36M | $32M | $19M | · | $32M | $30M | $15M | · | $-58M | $3M | $-54M | · | $-31M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $385M | $282M | $178M | $258M | $254M | $218M | $320M | $155M | $177M | $205M | $189M | $98M | $108M | $291M | $115M | $155M | |
| Receivables | $151M | $135M | $121M | $116M | $108M | $106M | $99M | $98M | $104M | $95M | · | $93M | $82M | $66M | · | $56M | |
| Inventory | $109M | $112M | $111M | $106M | $111M | $103M | $92M | $87M | $86M | $67M | · | $25M | $14M | $11M | · | $12M | |
| Prepaid Expense | $69M | $65M | $60M | $61M | $53M | $53M | $56M | $52M | $46M | $43M | · | $38M | $24M | $24M | · | $23M | |
| Current Assets | $1.22B | $1.10B | $1.06B | $1.08B | $961M | $871M | $938M | $788M | $729M | $675M | · | $499M | $493M | $503M | · | $522M | |
| PP&E (Net) | $17M | $15M | $8M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $17M | · | · | · | $14M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $10M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $103M | $106M | $109M | $112M | $114M | $117M | $120M | $106M | $108M | $110M | · | $67M | $68M | $70M | · | · | |
| Other Non-current Assets | $4M | $4M | $4M | $3M | $2M | $1M | $359.0K | $359.0K | $476.0K | $476.0K | · | $475.0K | $11M | $12M | · | $6M | |
| Total Assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Accounts Payable | $45M | $12M | $11M | $22M | $20M | $18M | $16M | $19M | $20M | $19M | · | $12M | $19M | $17M | · | $10M | |
| Accrued Liabilities | $317M | $293M | $266M | $335M | $310M | $284M | $379M | $325M | $318M | $311M | · | $197M | $169M | $207M | · | $107M | |
| Current Liabilities | $361M | $306M | $277M | $357M | $330M | $303M | $395M | $344M | $338M | $331M | · | $210M | $188M | $224M | · | $117M | |
| Capital Leases | $60M | $39M | $41M | $43M | $45M | $45M | $42M | $40M | $47M | $49M | · | $48M | $50M | $51M | · | $54M | |
| Deferred Tax | · | · | $11M | · | · | · | $11M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $15M | $13M | $19M | $14M | $29M | $20M | $18M | $15M | $12M | $11M | · | $13M | $9M | $5M | · | $6M | |
| Total Liabilities | $436M | $357M | $337M | $413M | $403M | $367M | $455M | $400M | $397M | $391M | · | $270M | $247M | $281M | · | $177M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | · | $16.0K | $16.0K | $16.0K | · | $16.0K | |
| Retained Earnings | $-1.78B | $-1.81B | $-1.81B | $-2.09B | $-2.16B | $-2.19B | $-2.20B | $-2.35B | $-2.38B | $-2.41B | · | $-2.48B | $-2.41B | $-2.41B | · | $-2.33B | |
| AOCI | $-958.0K | $-563.0K | $1M | $989.0K | $406.0K | $437.0K | $292.0K | $858.0K | $-339.0K | $-229.0K | · | $-319.0K | $-535.0K | $-220.0K | · | $-1M | |
| Stockholders' Equity | $1.31B | $1.25B | $1.23B | $917M | $822M | $765M | $733M | $577M | $517M | $464M | $432M | $362M | $396M | $374M | $400M | $426M | |
| Liabilities + Equity | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Shares Outstanding | 172,132,442 | 171,086,205 | 170,309,376 | 169,146,043 | 168,607,881 | 167,116,045 | 166,708,856 | 166,351,715 | 165,853,301 | 164,959,736 | · | 163,968,949 | 163,355,787 | 162,384,178 | · | 161,871,806 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $17M | $15M | $13M | $13M | $14M | $11M | $10M | $26M | $16M | $15M | $18M | $19M | $15M | $15M | $14M | $18M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $2M | $2M | $5M | $1M | $1M | $1M | $0 | $0 | $0 | |
| Operating Cash Flow | $101M | $34M | $-49M | $74M | $64M | $20M | $40M | $63M | $25M | $29M | $85M | $-59M | $8M | $-18M | $-24M | $-727.0K | |
| CapEx | $5M | $5M | $4M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | · | · | $0 | · | · | · | $0 | $0 | |
| Investing Cash Flow | $-9M | $66M | $-56M | $-79M | $-43M | $-124M | $122M | $-82M | $-56M | $-14M | $-347.0K | $34M | $-194M | $193M | $-18M | $15M | |
| Stock Issued | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Stock Activity | · | $4M | · | · | · | $2M | · | · | · | $1M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Change in Cash | $103M | $105M | $-82M | $4M | $37M | $-102M | $164M | $-19M | $-28M | $16M | $90M | $-12M | $-181M | $176M | $-40M | $15M | |
| Free Cash Flow | · | $29M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| Net Margin | 10.2% | 1.4% | · | 25.8% | 10.1% | 7.8% | · | 13.1% | 13.8% | 8.0% | · | -30.8% | 0.67% | -36.3% | · | -20.8% | |
| Pretax Margin | 15.1% | 1.5% | · | 16.0% | 15.2% | 11.4% | · | 15.5% | 15.4% | 10.2% | · | -24.6% | 3.8% | -37.9% | · | -20.2% | |
| EBITDA Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| ROA | 2.1% | 0.27% | · | 6.2% | 2.5% | 1.9% | · | 4.1% | 4.3% | 2.2% | · | -10.5% | 0.18% | -6.7% | · | -4.1% | |
| ROE | 3.0% | 0.36% | · | 9.6% | 4.0% | 3.1% | · | 7.0% | 7.3% | 4.0% | · | -16.6% | 0.27% | -10.5% | · | -5.5% | |
| ROIC | 2.0% | -0.34% | · | 6.3% | 2.6% | 1.7% | · | 4.6% | 5.3% | 2.6% | · | -19.9% | 0.13% | -13.7% | · | -7.5% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.6 | · | 3.0 | 2.9 | 2.9 | · | 2.3 | 2.2 | 2.0 | · | 2.4 | 2.6 | 2.2 | · | 4.5 | |
| Quick Ratio | 1.5 | 1.4 | · | 1.0 | 1.1 | 1.1 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | 1.0 | 1.6 | · | 1.8 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.6 | · | 0.8 | 0.6 | 0.1 | · | 0.2 | |
| Receivables Turnover | 2.4 | 2.2 | · | 2.6 | 2.5 | 2.4 | · | 2.6 | 2.6 | 2.6 | · | 2.9 | 2.2 | 1.8 | · | 2.2 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.59 | $7.29 | · | $5.42 | $4.88 | $4.58 | · | $3.47 | $3.12 | $2.81 | · | $2.21 | $2.42 | $2.30 | · | $2.63 | |
| Revenue / Share | $1.78 | $1.55 | · | $1.63 | $1.57 | $1.46 | · | $1.51 | $1.46 | $1.24 | · | $1289.01 | $1001.15 | $0.73 | · | $807.61 | |
| Cash Flow / Share | · | $0.20 | · | · | · | $0.12 | · | · | · | $0.17 | · | · | · | $-0.11 | · | · | |
| Cash / Share | $2.24 | $1.65 | · | $1.53 | $1.50 | $1.30 | · | $0.93 | $1.07 | $1.24 | · | $0.60 | $0.66 | $1.79 | · | $0.96 | |
| EPS (TTM) | $2.23 | $2.21 | · | $1.55 | $1.33 | $1.37 | · | $0.79 | $0.19 | $0.00 | · | $-0.92 | $-0.69 | $-0.91 | · | $-1.35 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.14B | $1.10B | · | $1.05B | $1.02B | $996M | · | $929M | $891M | $814M | · | $632M | $551M | $520M | · | $512M | |
| Net Income TTM | $380M | $376M | · | $261M | $222M | $229M | · | $129M | $31M | $-2M | · | $-149M | $-111M | $-146M | · | $-217M | |
| Market Cap | $4.35B | $3.81B | · | $3.61B | $3.64B | $2.78B | · | $2.56B | $2.70B | $3.05B | · | $3.42B | $3.91B | $3.06B | · | $2.65B | |
| P/E | 11.3 | 10.1 | · | 13.8 | 16.2 | 12.1 | · | 19.5 | 85.5 | · | · | -22.7 | -34.7 | -20.7 | · | -12.1 | |
| P/S | 3.8 | 3.5 | · | 3.4 | 3.6 | 2.8 | · | 2.8 | 3.0 | 3.7 | · | 5.4 | 7.1 | 5.9 | · | 5.2 | |
| P/B | 3.3 | 3.1 | · | 3.9 | 4.4 | 3.6 | · | 4.4 | 5.2 | 6.6 | · | 9.4 | 9.9 | 8.2 | · | 6.2 | |
| P / Tangible Book | 3.6 | 3.3 | · | 4.5 | 5.1 | 4.3 | · | 5.4 | 6.6 | 8.6 | · | 11.6 | 11.9 | 10.0 | · | 6.2 | |
| P / Cash Flow | · | 112.1 | · | · | · | 136.6 | · | · | · | 104.9 | · | · | · | -170.4 | · | · | |
| Earnings Yield | 8.8% | 9.9% | · | 7.3% | 6.2% | 8.2% | · | 5.1% | 1.2% | 0.00% | · | -4.4% | -2.9% | -4.8% | · | -8.2% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $1.07B | $958M | $726M | $517M | $484M |
| Bruttogewinnmarge % | · | · | 94.3% | 98.0% | 97.8% |
| Betriebsgewinnmarge % | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| Nettoergebnis | $391M | $226M | $-61M | $-216M | $-168M |
| Verwässerte EPS | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $105M | $157M | $17M | $-114M | $-127M |
Institutionelle Eigentümer (13F) 385 Einreicher · $4.7B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
385
Gehaltener Wert
$4.7B
Neue Positionen
49
Geschlossene Positionen
36
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 49 (-4 vs. Vorquartal) | 36 (+8 vs. Vorquartal) | 135 (+15 vs. Vorquartal) | 115 (-7 vs. Vorquartal) | +4.6M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $1.085.696.471 | 42.912.904 | 23,31% | Aktien |
| BlackRock, Inc. | $569.633.876 | 22.515.173 | 12,23% | Aktien |
| VANGUARD GROUP INC | $404.762.192 | 15.153.957 | 8,69% | Aktien |
| STATE STREET CORP | $229.628.164 | 9.076.212 | 4,93% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $223.612.785 | 8.838.450 | 4,80% | Aktien |
| RTW INVESTMENTS, LP | $180.756.457 | 7.144.524 | 3,88% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $145.822.875 | 5.763.750 | 3,13% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $93.482.749 | 3.694.988 | 2,01% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $84.977.229 | 3.358.129 | 1,82% | Aktien |
| Palo Alto Investors LP | $72.461.629 | 2.864.096 | 1,56% | Aktien |
| GOLDMAN SACHS GROUP INC | $65.276.910 | 2.580.115 | 1,40% | Aktien |
| Qube Research & Technologies Ltd | $61.899.233 | 2.446.610 | 1,33% | Aktien |
| Point72 Asset Management, L.P. | $61.559.150 | 2.433.168 | 1,32% | Aktien |
| CITADEL ADVISORS LLC | $55.209.078 | 2.182.177 | 1,19% | Aktien |
| Pictet Asset Management Holding SA | $50.146.450 | 1.983.198 | 1,08% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $49.826.959 | 1.969.445 | 1,07% | Aktien |
| MARSHALL WACE, LLP | $44.650.402 | 1.764.838 | 0,96% | Aktien |
| D. E. Shaw & Co., Inc. | $42.957.806 | 1.697.937 | 0,92% | Aktien |
| BRAIDWELL LP | $41.653.895 | 1.646.399 | 0,89% | Aktien |
| NORGES BANK | $41.069.692 | 1.623.308 | 0,88% | Aktien |
| Frazier Life Sciences Management, L.P. | $36.386.409 | 1.438.198 | 0,78% | Aktien |
| NORTHERN TRUST CORP | $34.595.776 | 1.367.422 | 0,74% | Aktien |
| Nuveen, LLC | $34.109.259 | 1.348.192 | 0,73% | Aktien |
| Artisan Partners Limited Partnership | $33.525.890 | 1.325.134 | 0,72% | Aktien |
| BANK OF AMERICA CORP /DE/ | $32.899.740 | 1.300.385 | 0,71% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $32.449.679 | 1.282.596 | 0,70% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $30.520.301 | 1.206.336 | 0,66% | Aktien |
| Allspring Global Investments Holdings, LLC | $28.540.663 | 1.132.566 | 0,61% | Aktien |
| Rockefeller Capital Management L.P. | $25.690.127 | 1.015.420 | 0,55% | Aktien |
| MORGAN STANLEY | $23.949.976 | 946.639 | 0,51% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $23.452.898 | 926.992 | 0,50% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $23.082.961 | 912.370 | 0,50% | Aktien |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $21.642.506 | 855.435 | 0,46% | Aktien |
| Invesco Ltd. | $20.504.689 | 810.462 | 0,44% | Aktien |
| PRINCIPAL FINANCIAL GROUP INC | $19.966.658 | 789.196 | 0,43% | Aktien |
| Bank of New York Mellon Corp | $19.243.919 | 760.629 | 0,41% | Aktien |
| Allianz Asset Management GmbH | $19.157.034 | 757.195 | 0,41% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $17.985.922 | 710.906 | 0,39% | Aktien |
| Fisher Asset Management, LLC | $17.690.535 | 699.230 | 0,38% | Aktien |
| FRED ALGER MANAGEMENT, LLC | $16.409.858 | 648.611 | 0,35% | Aktien |
| RICE HALL JAMES & ASSOCIATES, LLC | $15.657.841 | 618.887 | 0,34% | Aktien |
| AMERIPRISE FINANCIAL INC | $15.348.144 | 606.536 | 0,33% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $14.925.077 | 589.924 | 0,32% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $14.771.456 | 583.852 | 0,32% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $13.225.551 | 522.749 | 0,28% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12.903.000 | 510.000 | 0,28% | Aktien |
| GLENMEDE TRUST CO NA | $12.360.212 | 488.546 | 0,27% | Aktien |
| Hudson Bay Capital Management LP | $11.764.500 | 465.000 | 0,25% | Aktien |
| UBS Group AG | $11.639.341 | 460.053 | 0,25% | Aktien |
| JUPITER ASSET MANAGEMENT LTD | $11.599.190 | 458.466 | 0,25% | Aktien |
Aktivisten & 5%+-Eigentümer 6 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB3 LLC ×14 Einreichungen | 26. Februar 2026 | 25,40% | Änderung | · | SEC |
| Baker Bros. Advisors, LLC, Felix J. Baker, Julian C. Baker ×4 Einreichungen | 6. Juni 2013 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 2. Mai 2005 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 2. Mai 2005 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 2. Mai 2005 | · | Erste Einreichung | · | SEC |
| Oxford Bioscience Partners IV L.P., mRNA Fund II L.P., OBP Management IV L.P., Jeffrey T. Barnes, Mark P. Carthy, Jonathan J. Fleming, Michael E. Lytton, Alan G. Walton | 29. April 2005 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 42 Insider · 24 Führungskräfte · 21 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Adams Catherine Owen | Chief Executive Officer | 24. März 2026 M | 14.803 | 0 | 1 | $-249.932 |
| Stephen Davis | CEO | 19. August 2024 S | 186.555 | 0 | 0 | $0 |
| Uli Hacksell | CEO | 17. Februar 2015 M | 115.549 | 0 | 0 | $0 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | 6. August 2026 M | 67.828 | 0 | 9 | $-1.126.027 |
| Elena Ridloff | EVP and CFO | 29. April 2021 M | 10.553 | 0 | 0 | $0 |
| Todd S. Young | EVP AND CFO | 15. Oktober 2018 A | · | 0 | 0 | $0 |
| Thomas H Aasen | EXEC VP, CFO AND CBO | 4. April 2014 M | 0 | 0 | 0 | $0 |
| Srdjan R. Stankovic | President | 21. November 2022 M | 61.234 | 0 | 0 | $0 |
| Mark R Brann | President & CSO | 16. Juni 2006 S | 317.756 | 0 | 0 | $0 |
| Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | 17. November 2024 M | 62.105 | 0 | 0 | $0 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 29. Juli 2026 M | 18.994 | 0 | 3 | $-506.411 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 26. Juni 2026 S | 13.088 | 0 | 8 | $-602.789 |
| Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | 24. März 2026 M | 11.280 | 0 | 2 | $-245.022 |
| Thomas Garner | EVP, Chief Commercial Officer | 6. März 2026 A | · | 0 | 0 | $0 |
| Austin D. Kim | EVP,General Counsel, Secretary | 6. Januar 2024 M | 46.901 | 0 | 0 | $0 |
| Douglas J Williamson | Executive VP, Research & Dev | 10. Februar 2023 A | · | 0 | 0 | $0 |
| Michael J. Yang | EVP and CCO | 6. Januar 2021 M | 8.059 | 0 | 0 | $0 |
| Eric Alejandro Miller | Controller & PAO | 15. Oktober 2019 M | 270 | 0 | 0 | $0 |
| Glenn Baity | EVP AND GC | 18. April 2018 A | 83.734 | 0 | 0 | $0 |
| Terrence O Moore | EVP, CHIEF COMMERCIAL OFFICER | 8. März 2017 A | 1.671 | 0 | 0 | $0 |
| Roger Mills | EVP, DEVELOPMENT AND CMO | 20. März 2015 A | 18.550 | 0 | 0 | $0 |
| Bo-Ragnar Tolf | VP/Mg. Dir. ACADIA Pharma AB | 8. Juli 2009 M | 20.000 | 0 | 0 | $0 |
| Brian Lundstrom | Sr. VP, Bus. Development | 7. März 2008 A | 0 | 0 | 0 | $0 |
| Robert E Davis | Exec. VP, Drug Discovery | 11. März 2005 A | · | 0 | 0 | $0 |
| Adora Ndu | Direktor | 29. Mai 2026 A | 32.908 | 0 | 0 | $0 |
| Elizabeth A. Garofalo | Direktor | 29. Mai 2026 A | 33.489 | 0 | 0 | $0 |
| Jonathan Poole | Direktor | 29. Mai 2026 A | 2.010 | 0 | 0 | $0 |
| James M Daly | Direktor | 29. Mai 2026 A | 12.148 | 0 | 1 | $-671.100 |
| Laura Brege | Direktor | 29. Mai 2026 A | 23.202 | 0 | 0 | $0 |
| Edmund Harrigan | Direktor | 29. Mai 2026 A | 43.148 | 0 | 0 | $0 |
| Daniel B Soland | Direktor | 29. Mai 2025 A | 44.041 | 0 | 0 | $0 |
| Mary Ann Gray | Direktor | 7. Juni 2016 M | 149.476 | 0 | 0 | $0 |
| Leslie L Iversen | Direktor | 18. April 2016 M | 36.127 | 0 | 0 | $0 |
| Lester J Ph D Kaplan | Direktor | 11. August 2015 M | 17.000 | 0 | 0 | $0 |
| William Mcdowall Wells | Direktor | 15. Juni 2015 A | 0 | 0 | 0 | $0 |
| Torsten Rasmussen | Direktor | 15. Juni 2015 A | 8.500 | 0 | 0 | $0 |
| Michael T Borer | Direktor | 15. Juni 2015 A | 0 | 0 | 0 | $0 |
| Gordon M Binder | Direktor | 12. Juni 2009 A | 14.364 | 0 | 0 | $0 |
| Alan G Walton | Direktor | 12. Juni 2009 A | 25.979 | 0 | 0 | $0 |
| Martien Van Osch | Direktor | 10. Juni 2005 A | 1.168.892 | 0 | 0 | $0 |
| GORDON CARL L | Direktor | 20. April 2005 A | 774.006 | 0 | 0 | $0 |
| John Joseph Kaiser | · | 20. Oktober 2008 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 59 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IBRN · iShares Trust | 4,92% | 13.265 SH | 11. September 2026 | Täglich |
| PBE · Invesco Exchange-Traded Fund Trust | 1,82% | 383.853 SH | 1. Oktober 2026 | Täglich |
| BBP · ETFis Series Trust I | 1,69% | 64.350 NS | 31. Juli 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,40% | 124.236 SH | 1. Oktober 2026 | Täglich |
| RZG · Invesco Exchange-Traded Fund Trust | 0,97% | 57.480 SH | 1. Oktober 2026 | Täglich |
| LABU · Direxion Shares ETF Trust | 0,71% | 134.777 NS | 31. Juli 2026 | N-PORT |
| ROSC · Lattice Strategies Trust | 0,62% | 14.725 NS | 31. Juli 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,35% | 150.827 SH | 19. August 2026 | Täglich |
| IBB · iShares Trust | 0,35% | 1.293.913 SH | 11. September 2026 | Täglich |
| IWO · iShares Trust | 0,24% | 1.215.092 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,23% | 12.181 SH | 1. Oktober 2026 | Täglich |
| PWS · Pacer Funds Trust | 0,20% | 1.841 NS | 31. Juli 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,19% | 137.860 SH | 19. August 2026 | Täglich |
| BKSE · BNY Mellon ETF Trust | 0,19% | 6.256 NS | 31. Juli 2026 | N-PORT |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,17% | 19.976 SH | 1. Oktober 2026 | Täglich |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,17% | 443.221 SH | 19. August 2026 | Täglich |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,16% | 36.279 NS | 31. Juli 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,13% | 34.493 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,12% | 3.296.450 SH | 11. September 2026 | Täglich |
| ISCG · iShares Trust | 0,12% | 40.348 SH | 11. September 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,11% | 140.676 SH | 1. Oktober 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,10% | 741.237 SH | 19. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,09% | 559.090 NS | 31. Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,09% | 1.699.377 SH | 19. August 2026 | Täglich |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,08% | 40.712 NS | 31. Juli 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,05% | 52.423 SH | 1. Oktober 2026 | Täglich |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 10.893 NS | 31. Juli 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,05% | 2.295 NS | 31. Juli 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 54.681 NS | 31. Juli 2026 | N-PORT |
| IEUS · iShares Trust | 0,04% | 7.263 SH | 11. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1.457.036 SH | 19. August 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,04% | 2.944.095 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,04% | 346.329 SH | 19. August 2026 | Täglich |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,04% | 13.154 SH | 1. Oktober 2026 | Täglich |
| WSML · iShares Trust | 0,04% | 11.751 SH | 11. September 2026 | Täglich |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 4.009 SH | 1. Oktober 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,02% | 5.018 NS | 31. Juli 2026 | N-PORT |
| ISCF · iShares Trust | 0,02% | 13.099 SH | 11. September 2026 | Täglich |
| DFUV · Dimensional ETF Trust | 0,02% | 113.182 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 348.929 NS | 31. Juli 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,02% | 103.974 NS | 31. Juli 2026 | N-PORT |
| SCZ · iShares Trust | 0,02% | 238.968 SH | 9. September 2026 | Täglich |
| DCOR · Dimensional ETF Trust | 0,01% | 16.150 NS | 31. Juli 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,01% | 28.150 SH | 19. August 2026 | Täglich |
| DFAU · Dimensional ETF Trust | 0,01% | 39.121 NS | 31. Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 35.516 SH | 10. September 2026 | Täglich |
| ITOT · iShares Trust | 0,00% | 161.527 SH | 11. September 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,00% | 35.634 NS | 31. Juli 2026 | N-PORT |
| IEFA · iShares Trust | 0,00% | 240.578 SH | 11. September 2026 | Täglich |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.075.731 SH | 19. August 2026 | Täglich |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 100.076 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 10.781 SH | 19. August 2026 | Täglich |
| IJR · iShares Trust | · | 7.728.763 SH | 10. September 2026 | Täglich |
| IJT · iShares Trust | · | 1.198.794 SH | 9. September 2026 | Täglich |
| XJR · iShares Trust | · | 17.544 SH | 31. August 2026 | Täglich |
| ISCB · iShares Trust | · | 5.636 SH | 11. September 2026 | Täglich |
| SMLF · iShares Trust | · | 221.806 SH | 11. September 2026 | Täglich |
| SMMV · iShares Trust | · | 16.924 SH | 19. August 2026 | Täglich |
ACAD Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 27 Analysten
KAUF
Median-Ziel
$33.00
+65,4%
7 25,9%
Starker Kauf
14 51,9%
Kauf
5 18,5%
Halten
1 3,7%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
19 Analysten · 2026-09-29Mittelwert-Ziel $32.16 +61,2%
Jetzt
Aktueller Preis $19.95
Tief$17.00
Mittelwert$32.16
Hoch$49.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | · |
| IDYA | $3.04B | -27.0 | 3024.4% | -52.0% | -11.5% | · |
| VCYT | $3.34B | 51.3 | 16.0% | 12.8% | 5.2% | 70.1% |
| CELC | $4.81B | -26.3 | · | · | -244.3% | · |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | · |
| DNLI | $2.58B | -5.6 | 204.7% | · | -50.2% | · |
| RCUS | $2.99B | -7.2 | -4.3% | -142.9% | -59.8% | · |
| ARQT | $3.58B | -223.4 | 91.3% | -4.3% | -9.8% | · |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | · |
| PURR | $1.58B | 2.5 | · | 3229.8% | 24.8% | · |
| DYN | $3.23B | -5.6 | · | · | -57.8% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
BLUECHIP_DIP
Abgelaufen
Risiko 1
Belohnung 5,00
Einstieg
$21.20
R:R 5,00
BLUECHIP_DIP
Stop-Loss ausgelöst
Risiko 1
Belohnung 4,79
Einstieg
$21.86
R:R 4,79
BLUECHIP_DIP
Stop-Loss ausgelöst
Risiko 1
Belohnung 4,99
Einstieg
$22.45
R:R 4,99
Derzeit kein offenes Signal – keine Karte ist ausgefüllt, und das ist ehrlich.
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 5, 2026